News >

FDA Approves Pembrolizumab for PD-L1+ Cervical Cancer

Jason M. Broderick @jasoncology
Published: Tuesday, Jun 12, 2018

The FDA has granted pembrolizumab (Keytruda) an accelerated approval for the treatment of patients with advanced, PD-L1–positive cervical cancer with disease progression on or after chemotherapy.

Agilent Technologies also announced in a press release today that the FDA has approved its Dako PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic to identify patients with cervical cancer who are eligible for pembrolizumab based on their PD-L1 expression level. The assay had previously been approved for use in the non–small cell lung cancer and gastric or gastroesophageal junction adenocarcinoma settings.
Keytruda Prescribing Information. https://bit.ly/2HJOeUl. Accessed June 12, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x